ToddLouisRosenblatMD
Hematology • New York, NYHematologic Oncology
Assistant Professor of Medicine at Columbia University Medical Center, Div. of Hematology/Oncology New York-Presbyterian Hospital/Columbia University Medical Center
Overview of Dr. Rosenblat
Dr. Todd Rosenblat is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and Memorial Sloan Kettering Cancer Center. He received his medical degree from Stony Brook University Health Sciences Center School of Medicine and has been in practice 14 years. Dr. Rosenblat accepts several types of health insurance, listed below. He is one of 61 doctors at Memorial Sloan Kettering Cancer Center and one of 64 doctors at New York-Presbyterian Hospital who specialize in Hematology. He has more than 20 publications and over 500 citings.
Office
622 W 168th St
New York, NY 10032
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
NYU Grossman School of MedicineResidency, Internal Medicine, 2003 - 2006
Stony Brook University Health Sciences Center School of MedicineClass of 2003
Certifications & Licensure
NY State Medical License 2004 - 2026- American Board of Internal Medicine Hematology
Clinical Trials
- Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) Start of enrollment: 2010 Jun 01
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Publications & Presentations
PubMed
- 1546 citationsCD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaRenier J. Brentjens, Marco L. Davila, Isabelle Riviere, Jae H. Park, Xiuyan Wang
Science Translational Medicine. 2013-03-20 - 103 citationsPhase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.Peter Maslak, Tao Dao, Yvette Bernal, Suzanne Chanel, Rong Zhang
Blood Advances. 2018-02-13 - 157 citationsSequential Cytarabine and α-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid LeukemiaTodd L. Rosenblat, Michael R. McDevitt, Deborah Mulford, Neeta Pandit-Taskar, Chaitanya R. Divgi
Clinical Cancer Research. 2010-11-01
Abstracts/Posters
- Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution ExperienceTodd L. Rosenblat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...Todd L. Rosenblat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...Todd L. Rosenblat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPOMultiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
